MedTrace Logo

Pazopanib Maintenance for SCLC

NCT01797874 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2019-12-09

No results posted yet for this study

Summary

To evaluate the efficacy of pazopanib maintenance after 1st line CTx for SCLC.

Conditions

Interventions

DRUG

Pazopanib

Experimental

DRUG

Placebo

placebo arm

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2017-02-28
Completion
2017-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01797874 on ClinicalTrials.gov